# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# **SCHEDULE 13G**

### Under the Securities Exchange Act of 1934

# (Amendment No. 2)\*

Edesa Biotech, Inc.

(Name of Issuer)

Common Shares, no par value per share

(Title of Class of Securities)

27966L108

(CUSIP Number)

December 31, 2019

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

a. 🗆 Rule 13d-1(b)

b. ⊠ Rule 13d-1(c)

c.  $\Box$  Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 6

CUSIP No. 27966L108

1.	Names of Reporting Persons.					
	Mitchell P. Kopin					
2.	Check the Appropriate Box if a Member of a Group (See Instructions)					
	(a) □ (b) □					
3.	SEC Use Only					
4.	Citizenship or Place of Organization					
	United States of America					
		5.	Sole Voting Power			
			0			
Nu	mber of	6.	Shared Voting Power			
Shares	Beneficially		0			
	ed by Each porting	7.	Sole Dispositive Power			
	son With:		0			
		8.	Shared Dispositive Power			
			0			
9.	Aggregate Amount Beneficially Owned by Each Reporting Person					
	0 (see Item 4)					
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)					
11.	Percent of Class Represented by Amount in Row (9)					
	0% (see Item 4					
12. Type of Reporting Person (See Instructions)						
	IN; HC					

Page 2 of 6

CUSIP No. 27966L108

	r						
1.	Names of Reporting Persons.						
	Daniel B. Asher						
2.	Check the Appropriate Box if a Member of a Group (See Instructions)						
(a) □ (b) □							
3.	SEC Use Only						
4.	Citizenship or Place of Organization						
	United States of America						
		5.	Sole Voting Power				
			0				
N	Number of		Shared Voting Power				
Shares	Beneficially		0				
	ed by Each	7.	Sole Dispositive Power				
	eporting son With:	<i>.</i>					
1 010			0				
		8.	Shared Dispositive Power				
			0				
9.	Aggregate Amount Beneficially Owned by Each Reporting Person						
	0 (see Item 4)						
10.	0 (see Item 4)						
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)						
11.	Percent of Clas	ss Represe	nted by Amount in Row (9)				
	0% (see Item 4	0% (see Item 4)					
12.							
	IN; HC						

Page 3 of 6

CUSIP No. 27966L108

1.	Names of Rep	orting Per	2010				
1.	runnes of rep	Sitting I Ci	3013.				
	Intracoastal Capital LLC						
2.	Check the Appropriate Box if a Member of a Group (See Instructions)						
	(a) 🗆	(a) 🗆					
	(b) 🗆						
3.	SEC Use Only	SEC Use Only					
4.	Citizenship or	Organization					
	Delaware	5.	Sole Voting Power				
		5.	Sole voting rower				
			0				
N	lumber of	6.	Shared Voting Power				
Share	s Beneficially		0				
	ned by Each Reporting	7.	Sole Dispositive Power				
	erson With:		0				
		8.	Shared Dispositive Power				
			0				
9. Aggregate Amount Beneficially Owned by Each Reporting Person		ount Ben					
	0 (see Item 4)						
10.	, ,	0 (see Item 4) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)					
11.	Percent of Class Represented by Amount in Row (9)						
	0% (see Item 4)						
12.	Type of Reporting Person (See Instructions)						
	00						

Page 4 of 6

This Amendment No. 2 is being filed jointly by the Reporting Persons and amends the Schedule 13G initially filed by the Reporting Persons with the Securities and Exchange Commission (the "SEC") on June 4, 2018, as amended by Amendment No. 1 thereto filed by the Reporting Persons with the SEC on February 8, 2019 (the "Schedule 13G").

Except as set forth below, all Items of the Schedule 13G remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13G.

#### Item 1.

(a) Name of Issuer

Edesa Biotech, Inc. (the "Issuer")

(b) Address of Issuer's Principal Executive Offices

100 Spy Court Markham, Ontario, Canada L3R 5H6

#### Item 2.

(e) CUSIP Number

27966L108

#### Item 4. Ownership.

(a) and (b):

As of the close of business on December 31, 2019, each of the Reporting Persons may have been deemed to have beneficial ownership of no shares of Common Stock.

(c) Number of shares as to which each Reporting Person has:

(1) Sole power to vote or to direct the vote: \_\_\_\_\_.

(2) Shared power to vote or to direct the vote: <u>0</u>.

(3) Sole power to dispose or to direct the disposition of  $\underline{0}$ .

(4) Shared power to dispose or to direct the disposition of <u>0</u>.

### Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following b.

# **Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

Page 5 of 6

# SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 11, 2020

/s/ Mitchell P. Kopin Mitchell P. Kopin

/s/ Daniel B. Asher Daniel B. Asher

Intracoastal Capital LLC

By: /s/ Mitchell P. Kopin Mitchell P. Kopin, Manager

Page 6 of 6